Table 1.
Patient Characteristics and Comparative Prevalence of Advanced Fibrosis for Isolated HBcAb Compared to Other HBV Serologic Patterns
| Isolated HBcAb | Resolved HBV | Non-Immune HBV | HBsAb+ only | HBsAg+ | Total | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HIV | HIV/HCV | HIV | HIV/HCV | HIV | HIV/HCV | HIV | HIV/HCV | HIV | HIV/HCV | HIV | HIV/HCV | |
| N | 1504 | 2707 | 4283 | 2345 | 4089 | 1294 | 1471 | 452 | 849 | 492 | 12196 | 7290 |
| Age (Median, IQ) | 47 (44-54) | 48 (44-53) | 47 (40-55) | 48 (43-53) | 46* (39-54) | 46* (42-52) | 41* (32-50) | 47* (42-52) | 44* (38-52) | 46* (40-50) | 46 (39-54) | 48 (43-53) |
| Sex (%) | ||||||||||||
| Male | 98.7 | 99.0 | 98.6 | 98.5 | 95.1 | 96.8 | 96.0 | 96.2 | 98.8 | 99.4 | 97.1 | 98.3 |
| Ethnicity (%) | ||||||||||||
| White | 33.2 | 19.8 | 47.0* | 31.7* | 37.4* | 32.8* | 43.0* | 32.3* | 37.7* | 35.4 | 41.0 | 27.8 |
| Habits (%) | ||||||||||||
| Tobacco (current/past) | 59.8/14.6 | 74.2/14.1 | 48.4/17.9* | 68.2/15.5* | 53.4/16.6* | 69.4/13.2* | 45.4/13.8* | 63.1/15.4* | 57.2/11.6* | 66.0/13.8* | 51.6/16.1 | 70.2/14.5 |
| ETOH Abuse | 19.6 | 40.9 | 14.4* | 36.3* | 17.7* | 34.1* | 14.1* | 33.2* | 16.6 | 31.5* | 16.3 | 37.1 |
| Drug-Related Condition | 23.0 | 49.1 | 15.3* | 44.2* | 17.1* | 36.1* | 13.8* | 35.6* | 17.3* | 34.6* | 16.8 | 43.4 |
| ALT | 28 | 47 | 29 | 42* | 27 | 43* | 27 | 40* | 41* | 50 | 29 | 44 |
| AST | 29 | 50 | 28 | 42* | 28* | 41* | 26* | 41* | 42* | 50 | 28 | 45 |
| Log HIV-1 VL Undetectable (%) | 3.70 35.2% |
3.40 38.2% |
3.08* 44.9% |
3.28 40.0% |
3.48* 39.3% |
3.74* 35.0% |
3.15* 44.6% |
3.68 37.4% |
3.67 38.0% |
3.57 36.4% |
3.35 41.3% |
3.45 38.0% |
| CD4 (cells/μL) (%) | ||||||||||||
| CD4 <200 | 37.3 | 33.1 | 28.4* | 32.4 | 33.4* | 31.1 | 23.2* | 25.0* | 38.3 | 42.1* | 31.2 | 32.6 |
| Platelet (*1000/μL) | 214 | 191 | 218 | 196* | 221* | 205* | 227* | 202* | 180* | 180* | 218 | 195 |
| Comparative Prevalence of Advanced Fibrosis for Isolated HBcAb Compared to Other HBV Serologic Patterns, from Multivariable Logistic Regression Model | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Isolated HBcAb | Resolved HBV | Non-Immune HBV | HBsAb+ only | HBsAg+ | |||||
| HIV | HIV/HCV | HIV | HIV/HCV | HIV | HIV/HCV | HIV | HIV/HCV | ||
| FIB-4 >3.25 | Ref | 1.14 (0.85-1.53) | 1.34 (1.15-1.58) | 1.04 (0.78-1.39) | 1.32 (1.09-1.60) | 1.26 (0.84-1.89) | 1.65 (1.20-2.28) | 0.32 (0.23-0.44) | 0.75 (0.58-0.98) |
| APRI >2.0 | Ref | 1.16 (0.79-1.70) | 1.40 (1.15-1.71) | 1.42 (0.78-1.40) | 1.15 (0.92-1.44) | 1.67 (0.99-2.82) | 1.88 (1.25-2.84) | 0.22 (0.15-0.32) | 0.68 (0.51-0.91) |
| Platelets <140,000/μL | Ref | 0.97 (0.78-1.22) | 1.19 (1.02-1.40) | 1.16 (0.93-1.46) | 1.27 (1.05-1.54) | 1.15 (0.86-1.54) | 1.09 (0.82-1.44) | 0.49 (0.37-0.65) | 0.76 (0.60-0.99) |
*
p<0.0001, indicated group compared with isolated HBcAb patients
ETOH=Alcohol, IVDU=Intravenous Drug Use, FIB-4=FIB-4 fibrosis score, APRI=AST-to-platelet ratio index; All data from multivariable logistic regression model presented as Odds Ratio (95% confidence interval). Analyses were adjusted for age, race/ethnicity, CD4 count, log HIV VL, diabetes, body mass index, alcohol, drug use, smoking.